The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Erlotinib 150mg and bexarotene 400mg/m2 will be administered orally for 7-9 days prior to thoracotomy. Plasma samples will be collected on the day before surgery and along with tissue samples on the day of the thoracotomy. Analyses will be done on the resected specimen and it will be compared to the pre-study diagnostic specimen.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States
Number of Participants With Change in Expression Level of EGFR.
Time frame: Baseline and 9 days
Number of Participants With Change in Expression Level of Cyclin D1
Time frame: Baseline and 9 days
Number of Participants With Change in Expression Level of Phosphorylated EGFR (pEGFR)
Time frame: Baseline and 9 days
Tumor Tissue Concentrations of Erlotinib and Bexarotene and Correlation With Plasma Levels
Time frame: At 9 days
Number of Participants With EGFR Mutations and Correlation of EGFR Mutations With Response
Time frame: Baseline and 9 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.